Brochure

Myoma Radiofrequency Ablation

Uterine Fibroid Ablation, Built On a Legacy of RFA Innovation

Radiofrequency ablation (RFA) is transforming the landscape for myoma treatment. RFA can reduce the size of uterine fibroids and associated symptoms in an outpatient setting. RFA is a minimally invasive alternative to hysterectomy and myomectomy for the treatment of symptomatic uterine fibroids.^1-6

This brochure shows the innovative features of the CRF radiofrequency ablation system that boost physician confidence and ease of use.

Download the Brochure

Leading Power & Ease of Use

See how the CRF RFA System’s innovative features help clinicians find their focus for successful uterine fibroid.

Real-Time Audiovisual Feedback

Hear and see impedance changes during radiofrequency ablation procedure so you can keep your eyes on the ultrasound and patient.

Hands-Free Generator Operation

With an intuitive footswitch and pump synchronization, the RF generator frees your hands for the electrode and ultrasound transducer.

Automatic Electronic Records

The RF generator automatically logs readings for hundreds of procedures for easy record keeping and analysis.

CRF Electrodes Help Clinicians Hit the Target

For leiomyoma of varying size and FIGO type, clinicians trust the CRF RFA System’s cooled electrodes to hit the mark with precise treatment.

Sharp: The CRF electrode’s sharp tip and smooth insulation penetrate the tissue and myomas with ease.
Ergonomic: The CRF electrode’s lightweight, low-profile hub and lightweight cable facilitate probe placement and reduce disturbances.
Visible: The CRF electrode shows up clearly on ultrasound imaging and has shaft marks to indicate insertion depth.

Myoma Ablation Success Starts Here

The CRF RFA System is tailored for uterine fibroid ablation success. Its powerful, easy-to-use generator helps the doctor focus on the ultrasound and patient during ablation. Its low-profile cooled electrodes enhance access and ergonomics. The CRF system is trusted to make leiomyoma ablation more simple and efficient.

Download the brochure to see how the CRF RFA System’s innovation can lead the way for your myoma ablation program.

References

Santalla-Hernández et al. Clinical outcomes after 2-year follow-up of transvaginal radiofrequency ablation of symptomatic uterine fibroids. J Obstet Gynaecol Res. 2025 Jan;51(1):e16216.
Taheri et al. Nonresective treatments for uterine fibroids: a systematic review of uterine and fibroid volume reductions. Int J Hyperthermia. 2019;36(1):295-301.
Andersson et al. Minimally Invasive Management of Uterine Fibroids – Role of Transvaginal Radiofrequency Ablation. J Reprod Med Gynecol Obstet 2024;9.
Chen et al. Radiofrequency Ablation for the Treatment of Uterine Fibroids: A Systematic Review and Meta-Analysis by the AAGL Practice Committee. J Minim Invasive Gynecol. 2025 Jan;32(1):74-91.
ACOG Practice Bulletin No. 228: Management of Symptomatic Uterine Leiomyomas: Correction. Obstet Gynecol. 2021 Oct 1;138(4):683.
Havryliuk Y, Setton R, Carlow JJ, Shaktman BD. Symptomatic Fibroid Management: Systematic Review of the Literature. JSLS. 2017 Jul-Sep;21(3):e2017.00041.